Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Ovarian CancerEndometrial CancerCervical Cancer
Interventions
OTHER

Proactive immune tolerance induction

Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles

OTHER

Standard Treatment

Standard treatment throughout all chemotherapy cycles

DRUG

Paclitaxel and carboplatin

A chemotherapy regimen for gynecologic cancers.

DRUG

Standard premedication (20 mg)

Premedication includes 20 mg of dexamethasone.

DRUG

Reduced premedication (10 mg)

Premedication includes 20 mg of dexamethasone.

DRUG

Reduced premedication (5 mg)

Premedication includes 5 mg of dexamethasone.

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Seoul National University Boramae Hospital

OTHER

collaborator

Korea Health Industry Development Institute

OTHER_GOV

lead

Seoul National University Hospital

OTHER